Clinical Trials
10 trialsNCT00557193 2024-07-15
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Completed
NCT00084422 2023-04-10
N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT00469859 2017-03-15
Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Children's Oncology Group
Phase 1/2 Completed
NCT00079482 2016-07-21
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00586651 2015-10-08
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00668421 2014-11-26
CEP-701 (Lestaurtinib) in Myelofibrosis
Icahn School of Medicine at Mount Sinai
Phase 1/2 Unknown
NCT00081601 2012-08-24
Study of CEP-701 in Treatment of Prostate Cancer
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00030186 2012-08-23
Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00242827 2012-08-23
Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Terminated
NCT00494585 2012-06-25
CEP-701 for PH-negative Myelofibrosis
M.D. Anderson Cancer Center
Phase 2 Completed